When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.
In support of improving patient care, this activity has been planned and implemented by Springer Healthcare IME and HMP Education and will be certified with 0.5 AMA PRA Category 1 Credits™. You must fill out the evaluation form at the end if you would like to receive accreditation for your participation in this activity.
Professor of Medicine at Harvard Medical School (HMS), USA
Faculty member in the Neuroendocrine & Pituitary Tumor Clinical Center at Massachusetts General Hospital (MGH) in Boston, Massachusetts, USA
Dr. Biller is Program Director of the Clinical Fellowship in Adult Endocrinology and Metabolism at MGH. She also directs the annual HMS & MGH Continuing Medical Education course “Clinical Endocrinology” that welcomes endocrinologists from around the world to Boston every Spring.
Major research interests include the diagnosis and treatment of Cushing’s disease, acromegaly, prolactinomas, and growth hormone deficiency (GHD) in adults. Dr. Biller has published original research in many peer-reviewed journals and has co-authored clinical guidelines regarding Cushing’s disease for the Endocrine and Pituitary Societies, on pituitary adenomas in pregnancy for the European Society of Endocrinology and on adult GHD for the American Association of Clinical Endocrinologists.
Dr. Biller discloses a grant received from Ascendis, consulting/Honoraria from Merck Serono and consulting honoraria from Novo Nordisk.
All relevant financial relationships have been mitigated.
Professor Shalet is an Honorary Consultant Endocrinologist at the Christie Hospital, Manchester and Emeritus Professor of Endocrinology at the University of Manchester, UK. He completed a BSc in Physiology at London University and qualified in medicine at the Royal London Hospital. Hospital medical training posts in London and Bristol were followed by an appointment as Research Fellow in Endocrinology at the Christie Hospital, Manchester.
Professor Shalet has extensive research interests in the late endocrine effects following treatment of cancer, pituitary disorders and in particular abnormalities of growth hormone secretion He is the author/co-author of over 500 articles and more than 200 of these are related to clinical disorders of the GH-IGF-1 axis and/or therapeutic use of GH therapy in man.
Previous positions and official activities include Chairman of the Strategic Planning Committee of the European Society of Pediatric Endocrinology, Co-Editor of the first edition of the Oxford Textbook of Endocrinology and a member of the Council of the Society for Endocrinology and the SAC in Endocrinology and Diabetes. Professor Shalet has served as President of the Endocrine Section of the Royal Society of Medicine, as a member of the Council of the European Society of Paediatric Endocrinology, was Chairman of the Specialist Training Committee in Diabetes and Endocrinology for the North West Region and as a member of the Clinical Practice Committee of the Society for Endocrinology.
Professor Shalet discloses grants or honoraria received from NovoNordisk, Saizen and Merck. All relevant financial relationships have been mitigated.
In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare IME. HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
HMP Education designates AMA PRA Category Credit(s)™ for the following activities:
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In addition to the speaker faculty, HMP Education and Springer Healthcare IME planners and staff include Randy Robin, Rachel Goddard & Alba Ruzafa.
Randy Robbin, Rachel Goddard and Alba Ruzafa have no financial relationships to disclose.